Form 8-K - Current report:
SEC Accession No. 0001564590-22-027108
Filing Date
2022-07-29
Accepted
2022-07-29 16:12:14
Documents
13
Period of Report
2022-07-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K imra-8k_20220725.htm   iXBRL 8-K 42988
2 EX-10.1 imra-ex101_24.htm EX-10.1 59081
  Complete submission text file 0001564590-22-027108.txt   245308

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA imra-20220725.xsd EX-101.SCH 5569
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE imra-20220725_lab.xml EX-101.LAB 20072
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE imra-20220725_pre.xml EX-101.PRE 11919
7 EXTRACTED XBRL INSTANCE DOCUMENT imra-8k_20220725_htm.xml XML 3665
Mailing Address 116 HUNTINGTON AVENUE 6TH FLOOR BOSTON MA 02116
Business Address 116 HUNTINGTON AVENUE 6TH FLOOR BOSTON MA 02116 617-206-2020
IMARA Inc. (Filer) CIK: 0001672619 (see all company filings)

EIN.: 811523849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39247 | Film No.: 221120938
SIC: 2834 Pharmaceutical Preparations